...
首页> 外文期刊>American Journal of Neuroradiology >Predictive Value of Lesions for Relapses in Relapsing-remitting Multiple Sclerosis
【24h】

Predictive Value of Lesions for Relapses in Relapsing-remitting Multiple Sclerosis

机译:复发-缓解型多发性硬化症病变对复发的预测价值

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND AND PURPOSE: Recent studies have suggested that enhancing lesions on contrast-enhanced T1-weighted MR images are predictive of impending exacerbations in cases of relapsing-remitting multiple sclerosis. We examined whether enhancing lesions, new enhancing lesions, and new hypointense lesions ("black holes") could accurately predict exacerbations in a cohort of 50 patients with relapsing-remitting multiple sclerosis within a time frame of up to 6 months. METHODS: Data were obtained from 50 patients with relapsing-remitting disease. All patients underwent monthly MR imaging and clinical examinations for a period of 12 months. Putative predictors of clinical relapse were defined from enhancing lesions, new enhancing lesions, and new black hole outcomes, and their operating characteristics were studied. RESULTS: Overall, the positive predictive values (PV+) of enhancing lesions, new enhancing lesions, or new black holes for an exacerbation did not exceed 0.25 and the negative predictive values (PV-) were all near 0.9. The best predictor for new enhancing lesions was the occurrence of new enhancing lesions in each of the previous 3 months (PV+: 0.79 [95% confidence interval, 0.651–0.900]; PV-: 0.83 [95% confidence interval, 0.751–0.887]). Similarly, new black holes were predicted best by the occurrence of new black holes in each of the previous 2 months (PV+: 0.54 [95% confidence interval: 0.372–0.697]; PV-: 0.85 [95% confidence interval, 0.790–0.896]). CONCLUSION: None of the MR markers could predict an impending relapse with any reasonable degree of precision. Rather, the absence of MR markers is associated with a more favorable clinical course (ie, fewer relapses).
机译:背景与目的:最近的研究表明,在增强后的多次 <病例中,对比增强的T1加权MR图像上的 病变可预示即将发作的病情加重。 / sup>硬化。我们检查了增强病变,新增强 病变和新的低性病变(“黑洞”)是否可以准确地 预测一组复发缓解的50名患者的病情加重> 多发性硬化症,病程最长不超过6个月。 方法:数据来自50例复发缓解型 疾病患者。所有患者均接受每月MR成像和临床 检查,为期12个月。通过增强病灶,新的 病灶和新的黑洞预后定义了临床复发的假定预测因素,并研究了它们的手术特征。 结果:总体而言,强化 病变,新的强化病变或新的黑洞加重 的阳性预测值(PV +)不超过0.25负预测值(PV-) 都接近0.9。新的增强病变最好的预测指标是在前三个月的每个月中都出现新的增强病变(PV +:0.79 [95%置信区间,0.651-0.900]; PV-:0.83 [95%置信区间,0.751–0.887]。同样, 通过在过去两个月的每个月中都出现新的 黑洞,可以最好地预测新的黑洞(PV +:0.54 [95% 置信区间:0.372–0.697]; PV-:0.85 [95%置信区间 区间,0.790–0.896])。 结论:所有MR标记均无法预测即将发生的< sup> 以任何合理的精度复发。相反, 不存在MR标记与更有利的临床 病程(即复发率更低)相关。

著录项

  • 来源
    《American Journal of Neuroradiology》 |2001年第2期|284-291|共8页
  • 作者单位

    From the Department of Molecular and Experimental Medicine (J.A.K., S.W., L.S.S., J.C.S., H.-P.A.), The Scripps Research Institute, the Department of Radiology (D.F.S.) and the Division of Neurology (J.S.R., J.C.S.), Scripps Clinic, La Jolla, CA, and the Department of Neurology (S.W.), Ruprecht-Karls University, Heidelberg, Germany.;

    From the Department of Molecular and Experimental Medicine (J.A.K., S.W., L.S.S., J.C.S., H.-P.A.), The Scripps Research Institute, the Department of Radiology (D.F.S.) and the Division of Neurology (J.S.R., J.C.S.), Scripps Clinic, La Jolla, CA, and the Department of Neurology (S.W.), Ruprecht-Karls University, Heidelberg, Germany.;

    From the Department of Molecular and Experimental Medicine (J.A.K., S.W., L.S.S., J.C.S., H.-P.A.), The Scripps Research Institute, the Department of Radiology (D.F.S.) and the Division of Neurology (J.S.R., J.C.S.), Scripps Clinic, La Jolla, CA, and the Department of Neurology (S.W.), Ruprecht-Karls University, Heidelberg, Germany.;

    From the Department of Molecular and Experimental Medicine (J.A.K., S.W., L.S.S., J.C.S., H.-P.A.), The Scripps Research Institute, the Department of Radiology (D.F.S.) and the Division of Neurology (J.S.R., J.C.S.), Scripps Clinic, La Jolla, CA, and the Department of Neurology (S.W.), Ruprecht-Karls University, Heidelberg, Germany.;

    From the Department of Molecular and Experimental Medicine (J.A.K., S.W., L.S.S., J.C.S., H.-P.A.), The Scripps Research Institute, the Department of Radiology (D.F.S.) and the Division of Neurology (J.S.R., J.C.S.), Scripps Clinic, La Jolla, CA, and the Department of Neurology (S.W.), Ruprecht-Karls University, Heidelberg, Germany.;

    From the Department of Molecular and Experimental Medicine (J.A.K., S.W., L.S.S., J.C.S., H.-P.A.), The Scripps Research Institute, the Department of Radiology (D.F.S.) and the Division of Neurology (J.S.R., J.C.S.), Scripps Clinic, La Jolla, CA, and the Department of Neurology (S.W.), Ruprecht-Karls University, Heidelberg, Germany.;

    From the Department of Molecular and Experimental Medicine (J.A.K., S.W., L.S.S., J.C.S., H.-P.A.), The Scripps Research Institute, the Department of Radiology (D.F.S.) and the Division of Neurology (J.S.R., J.C.S.), Scripps Clinic, La Jolla, CA, and the Department of Neurology (S.W.), Ruprecht-Karls University, Heidelberg, Germany.;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号